1-20 of 145
Drug Resistance
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

On-Target BTK Mutations Promote Resistance to Noncovalent BTK Inhibitors

Journal: Cancer Discovery
Cancer Discov (2022) 12 (5): 1179.
DOI: https://doi.org/10.1158/2159-8290.CD-RW2022-041
Published: 02 May 2022
View article
PDF
Journal Articles

Two Driver Mutations Exist in Osimertinib-Resistant Patient Tumors

Journal: Cancer Discovery
Cancer Discov (2022) 12 (4): OF3.
DOI: https://doi.org/10.1158/2159-8290.CD-RW2022-019
Published: 01 April 2022
View article
Journal Articles

Abstract GS3-09: Loss of ASXL1 tumor suppressor promotes resistance to CDK4/6 inhibitors in ER+ breast cancer

Dhivya R. Sudhan, Sumanta Chatterjee, Jiwoong Kim, Yunguan Wang, Vishal Kandagatla, Dan Ye, Chang-Ching Lin, Jorge Gomez Tejeda Zanudo, Esha Jain, Arnaldo Marin, Alberto Servetto, Kyung-min Lee, Juan Manuel Povedano, David McFadden, Alex Barrett, Nikhil Wagle, Ariella B. Hanker, Carlos L. Arteaga
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): GS3-09.
DOI: https://doi.org/10.1158/1538-7445.SABCS21-GS3-09
Published: 15 February 2022
View article
Journal Articles

Abstract P4-01-07: Insights into the compensation mechanism behind targeting PI3K and Wnt in triple-negative breast cancer

Jeffrey P Solzak, Chao Wang, Milan Radovich
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): P4-01-07.
DOI: https://doi.org/10.1158/1538-7445.SABCS21-P4-01-07
Published: 15 February 2022
View article
Journal Articles

Abstract P4-01-06: Genomic and transcriptomic analysis reveals known and novel resistance mechanisms to CDK4/6 inhibitors and sensitivity factors for the response to triplet therapy (palbociclib + everolimus + exemestane) in a phase I/IIb study in hormone-receptor positive (HR+)/HER2- metastatic breast cancer (MBC) after progression on a CDK4/6 inhibitor (CDK4/6i)

Jorge Gomez Tejeda Zanudo, Romualdo Barroso-Sousa, Esha Jain, Jorge Buendia-Buendia, Tianyu Li, Nabihah Tayob, Rebecca Rees, Alyssa Pereslete, Arlindo R. Ferreira, Daniel L. Abravanel, Karla Helvie, Ann H. Partridge, Beth Overmoyer, Eric P. Winer, Nikhil Wagle, Sara M. Tolaney
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): P4-01-06.
DOI: https://doi.org/10.1158/1538-7445.SABCS21-P4-01-06
Published: 15 February 2022
View article
Journal Articles

Abstract P4-01-18: Acquired sensitivity strategies in ER+ breast cancer progressing on CDK4/6 and mTOR inhibitors

Eleni Farmaki, Rena Emond, Patrick Cosgrove, Andrea Bild
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): P4-01-18.
DOI: https://doi.org/10.1158/1538-7445.SABCS21-P4-01-18
Published: 15 February 2022
View article
Journal Articles

Abstract P4-01-05: Multi-omics data shows downregulation of mismatch repair, purin and tublin pathways in AR-negative triple-negative chemotherapy-resistant tumors

Krishna R Kalari, Vera J Suman, Xiaojia Tang, Jason P Sinnwell, Kevin J Thompson, Peter T Vedell, Jodi M Carter, Sarah A McLaughlin, Alvaro Moreno Aspitia, Donald W Northfelt, Richard J Gray, Richard Weinshilboum, Liewei Wang, Judy C Boughey, Matthew Goetz
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): P4-01-05.
DOI: https://doi.org/10.1158/1538-7445.SABCS21-P4-01-05
Published: 15 February 2022
View article
Journal Articles

Abstract P4-01-04: FGFR inhibitor mediated dismissal of SWI/SNF complexes from YAP-dependent enhancers induces therapeutic resistance in triple negative breast cancer

Yihao Li, Xintao Qiu, Xiaoqing Wang, Hui Liu, Renee Geck Geck, Alok Tewari, Kin-Hoe Chow, Tengfei Xiao, Paloma Cejas, Quang-Dé Nguyen, Henry Long, Shirley X Liu, Alex Toker, Myles Brown
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): P4-01-04.
DOI: https://doi.org/10.1158/1538-7445.SABCS21-P4-01-04
Published: 15 February 2022
View article
Journal Articles

Abstract P4-01-11: UBQLN4 regulates cisplatin-resistance in triple-negative breast cancer by targeting BAT3 for proteasomal degradation

Yoshiaki Shoji, Takamichi Yokoe, Peter J Bostick, Yosef Shiloh, Dave SB Hoon, Matias A Bustos
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): P4-01-11.
DOI: https://doi.org/10.1158/1538-7445.SABCS21-P4-01-11
Published: 15 February 2022
View article
Journal Articles

Abstract P4-01-10: A kinase inhibitor library screen reveals novel candidates that reverse CDK4/6 inhibitor resistance in CDK6 amplified HR(+) breast cancer

Jiun-I Lai, Yong-Ji Zhuang, Ting-Yi Lin, Ta-Chung Chao, Chun-Yu Liu, Ling-Ming Tseng
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): P4-01-10.
DOI: https://doi.org/10.1158/1538-7445.SABCS21-P4-01-10
Published: 15 February 2022
View article
Journal Articles

Abstract P4-01-03: Multiomics data reveal novel biomarkers for CDK4/6 resistance

Krishna R. Kalari, Kevin J. Thompson, Jason Sinnwell, Xiaojia Tang, Vera J. Suman, Jun He, Seul Kee Byeon, Akhilesh Pandey, Abe Eyman Casey, Peter T. Vedell, Ann M. Moyer, Alvaro Moreno-Aspitia, Donald W. Northfelt, Minetta C. Liu, Tufia C. Haddad, Saranya Chumsri, Prema Peethambaram, Kathryn J. Ruddy, Karthik V. Giridhar, Roberto A. Leon-Ferre, Richard M. Weinshilboum, Liewei Wang, Ciara C. O’ Sullivan, Matthew P. Goetz
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): P4-01-03.
DOI: https://doi.org/10.1158/1538-7445.SABCS21-P4-01-03
Published: 15 February 2022
View article
Journal Articles

Abstract P4-01-02: A spectrum of secondary mutations in HER2 augment breast cancer cell growth and reduce neratinib sensitivity in HER2-mutant breast cancer

Arnaldo Andres Marin, Abdullah Al Mamun, Hiroaki Akamatsu, Dan Ye, Dhivya Sudhan, Benjamin Brown, Monica Red Brewer, Lisa Eli, Jens Meiler, Carlos L Arteaga, Ariella B Hanker
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): P4-01-02.
DOI: https://doi.org/10.1158/1538-7445.SABCS21-P4-01-02
Published: 15 February 2022
View article
Journal Articles

Abstract P4-01-15: Eribulin treatment for hormone receptor positive breast cancer cells with resistant to endocrine therapy promotes re-expression of estrogen receptor

Wataru Goto, Shinichiro Kashiwagi, Misato Fujioka, Sae Ishihara, Yuka Asano, Tamami Morisaki, Satoru Noda, Tsutomu Takashima, Masaichi Ohira, Kosei Hirakawa
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): P4-01-15.
DOI: https://doi.org/10.1158/1538-7445.SABCS21-P4-01-15
Published: 15 February 2022
View article
Journal Articles

Abstract P4-01-14: The RXR agonist, IRX4204, increases the anti-tumor activity of HER2-targeted therapies in HER2-amplified breast cancer

Cassandra L Moyer, Abhijit Mazumdar, Jamal Hill, Martin E Sanders, Powel Brown
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): P4-01-14.
DOI: https://doi.org/10.1158/1538-7445.SABCS21-P4-01-14
Published: 15 February 2022
View article
Journal Articles

Abstract P4-01-01: Resistance to next generation tyrosine kinase inhibitors (TKIs) in HER2-positive breast cancer (BC): Role of HER and PIK3CA mutations and development of new treatment strategies and study models

Sreyashree Bose, Ragini Mistry, Chia Chia Liu, Sarmistha Nanda, Lanfang Qin, Pier Selenica, Andrea Gazzo, Yingjie Zhu, Michael A. Mancini, Fabio Stossi, Irmina Diala, Lisa D. Eli, Britta Weigelt, Jorge S. Reis-Filho, Mothaffar F. Rimawi, C. Kent Osborne, Rachel Schiff, Jamunarani Veeraraghavan
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): P4-01-01.
DOI: https://doi.org/10.1158/1538-7445.SABCS21-P4-01-01
Published: 15 February 2022
View article
Journal Articles

Abstract P4-01-09: The WAVE3 phosphorylation/β-catenin oncogenic signaling axis promotes chemoresistance and cancer stemness in triple negative breast cancer

Wei Wang, Priyanka Rana, Akram Alkrekshi, Vesna Markovic, Khalid Sossey-Alaoui
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): P4-01-09.
DOI: https://doi.org/10.1158/1538-7445.SABCS21-P4-01-09
Published: 15 February 2022
View article
Journal Articles

Abstract P4-01-08: Morphological and functional plasticity of mitochondria in chemoresistant triple negative breast cancer

Lily Mokryun Baek, Junegoo Lee, James P. Barrish, Bora Lim, Jeffrey T. Chang, Phillip L. Lorenzi, Weston Porter, Gloria V. Echeverria
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): P4-01-08.
DOI: https://doi.org/10.1158/1538-7445.SABCS21-P4-01-08
Published: 15 February 2022
View article
Journal Articles

Abstract P4-01-17: Preventing adaptive therapeutic resistance to CDK4/6 inhibition with CDK8/19 inhibitors

Zachary Mack, Margarita Yastrebova, Alvina Khamidullina, Amanda Sharko, Xiaokai Ding, Stephan Bowe, Nikitha Sashi, Samantha Safa, Kaitlyn Digsby, Amanda Eckstrom, Vitali Sikirzhitski, Chang-uk Lim, Victor Tatarskiy, Igor Roninson, Eugenia Broude
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): P4-01-17.
DOI: https://doi.org/10.1158/1538-7445.SABCS21-P4-01-17
Published: 15 February 2022
View article
Journal Articles

Abstract P4-01-16: Overcome chemoresistance of triple-negative breast cancer by inhibiting the RNA-binding protein HuR

Lanjing Wei, Qi Zhang, Cuncong Zhong, Jeffrey Aubé, Danny R. Welch, Xiaoqing Wu, Liang Xu
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): P4-01-16.
DOI: https://doi.org/10.1158/1538-7445.SABCS21-P4-01-16
Published: 15 February 2022
View article
Journal Articles

Abstract P4-01-13: Low tumor TLR9 expression results in resistance to growth inhibitory and autophagy responses to common breast cancer treatments

Katri Selander, Juha Klaper, Nataliia Petruk, Mauricio Ramm, Arja Jukkola, Eeva-Liisa Eskelinen
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): P4-01-13.
DOI: https://doi.org/10.1158/1538-7445.SABCS21-P4-01-13
Published: 15 February 2022
View article